Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma

Hypercalcitoninemia has frequently been reported as a marker for medullary thyroid carcinoma. Currently, calcitonin measurements are mostly useful in the evaluation of tumor size and progression, and as an index of biochemical improvement of medullary thyroid carcinomas. Although measurement of calcitonin is a highly sensitive method for the detection of medullary thyroid carcinoma, it presents a low specificity for this tumor. Several physiologic and pathologic conditions other than medullary thyroid carcinoma have been associated with increased levels of calcitonin. Several cases of thyroid nodules associated with increased values of calcitonin are not medullary thyroid carcinomas, but rather are related to other conditions, such as hypercalcemias, hypergastrinemias, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, and goiter. Furthermore, prolonged treatment with omeprazole (> 2-4 months), beta-blockers, glucocorticoids and potential secretagogues, have been associated with hypercalcitoninemia. An association between calcitonin levels and chronic auto-immune thyroiditis remains controversial. Patients with calcitonin levels >100 pg/mL have a high risk for medullary thyroid carcinoma (~90%-100%), whereas patients with values from 10 to 100 pg/mL (normal values: <8.5 pg/mL for men, < 5.0 pg/mL for women; immunochemiluminometric assay) have a <25% risk for medullary thyroid carcinoma. In multiple endocrine neoplasia type 2 (MEN2), RET mutation analysis is the gold-standard for the recommendation of total preventive thyroidectomy to relatives at risk of harboring a germline RET mutation (50%). False-positive calcitonin results within MEN2 families have led to incorrect indications of preventive total thyroidectomy to RET mutation negative relatives. In this review, we focus on the differential diagnosis of hypercalcitoninemia, underlining its importance for the avoidance of misdiagnosis of medullary thyroid carcinoma and consequent incorrect recommendation for thyroid surgery.

Saved in:
Bibliographic Details
Main Authors: Toledo,Sergio PA, Lourenço Jr,Delmar M, Santos,Marcelo Augusto, Tavares,Marcos R, Toledo,Rodrigo A, Correia-Deur,Joya Emilie de Menezes
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2009
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000700015
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322009000700015
record_format ojs
spelling oai:scielo:S1807-593220090007000152009-07-22Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinomaToledo,Sergio PALourenço Jr,Delmar MSantos,Marcelo AugustoTavares,Marcos RToledo,Rodrigo ACorreia-Deur,Joya Emilie de Menezes Calcitonin False-positive test RET mutation Total thyroidectomy Hypercalcitoninemia has frequently been reported as a marker for medullary thyroid carcinoma. Currently, calcitonin measurements are mostly useful in the evaluation of tumor size and progression, and as an index of biochemical improvement of medullary thyroid carcinomas. Although measurement of calcitonin is a highly sensitive method for the detection of medullary thyroid carcinoma, it presents a low specificity for this tumor. Several physiologic and pathologic conditions other than medullary thyroid carcinoma have been associated with increased levels of calcitonin. Several cases of thyroid nodules associated with increased values of calcitonin are not medullary thyroid carcinomas, but rather are related to other conditions, such as hypercalcemias, hypergastrinemias, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, and goiter. Furthermore, prolonged treatment with omeprazole (> 2-4 months), beta-blockers, glucocorticoids and potential secretagogues, have been associated with hypercalcitoninemia. An association between calcitonin levels and chronic auto-immune thyroiditis remains controversial. Patients with calcitonin levels >100 pg/mL have a high risk for medullary thyroid carcinoma (~90%-100%), whereas patients with values from 10 to 100 pg/mL (normal values: <8.5 pg/mL for men, < 5.0 pg/mL for women; immunochemiluminometric assay) have a <25% risk for medullary thyroid carcinoma. In multiple endocrine neoplasia type 2 (MEN2), RET mutation analysis is the gold-standard for the recommendation of total preventive thyroidectomy to relatives at risk of harboring a germline RET mutation (50%). False-positive calcitonin results within MEN2 families have led to incorrect indications of preventive total thyroidectomy to RET mutation negative relatives. In this review, we focus on the differential diagnosis of hypercalcitoninemia, underlining its importance for the avoidance of misdiagnosis of medullary thyroid carcinoma and consequent incorrect recommendation for thyroid surgery.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.64 n.7 20092009-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000700015en10.1590/S1807-59322009000700015
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Toledo,Sergio PA
Lourenço Jr,Delmar M
Santos,Marcelo Augusto
Tavares,Marcos R
Toledo,Rodrigo A
Correia-Deur,Joya Emilie de Menezes
spellingShingle Toledo,Sergio PA
Lourenço Jr,Delmar M
Santos,Marcelo Augusto
Tavares,Marcos R
Toledo,Rodrigo A
Correia-Deur,Joya Emilie de Menezes
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
author_facet Toledo,Sergio PA
Lourenço Jr,Delmar M
Santos,Marcelo Augusto
Tavares,Marcos R
Toledo,Rodrigo A
Correia-Deur,Joya Emilie de Menezes
author_sort Toledo,Sergio PA
title Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
title_short Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
title_full Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
title_fullStr Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
title_full_unstemmed Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
title_sort hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
description Hypercalcitoninemia has frequently been reported as a marker for medullary thyroid carcinoma. Currently, calcitonin measurements are mostly useful in the evaluation of tumor size and progression, and as an index of biochemical improvement of medullary thyroid carcinomas. Although measurement of calcitonin is a highly sensitive method for the detection of medullary thyroid carcinoma, it presents a low specificity for this tumor. Several physiologic and pathologic conditions other than medullary thyroid carcinoma have been associated with increased levels of calcitonin. Several cases of thyroid nodules associated with increased values of calcitonin are not medullary thyroid carcinomas, but rather are related to other conditions, such as hypercalcemias, hypergastrinemias, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, and goiter. Furthermore, prolonged treatment with omeprazole (> 2-4 months), beta-blockers, glucocorticoids and potential secretagogues, have been associated with hypercalcitoninemia. An association between calcitonin levels and chronic auto-immune thyroiditis remains controversial. Patients with calcitonin levels >100 pg/mL have a high risk for medullary thyroid carcinoma (~90%-100%), whereas patients with values from 10 to 100 pg/mL (normal values: <8.5 pg/mL for men, < 5.0 pg/mL for women; immunochemiluminometric assay) have a <25% risk for medullary thyroid carcinoma. In multiple endocrine neoplasia type 2 (MEN2), RET mutation analysis is the gold-standard for the recommendation of total preventive thyroidectomy to relatives at risk of harboring a germline RET mutation (50%). False-positive calcitonin results within MEN2 families have led to incorrect indications of preventive total thyroidectomy to RET mutation negative relatives. In this review, we focus on the differential diagnosis of hypercalcitoninemia, underlining its importance for the avoidance of misdiagnosis of medullary thyroid carcinoma and consequent incorrect recommendation for thyroid surgery.
publisher Faculdade de Medicina / USP
publishDate 2009
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000700015
work_keys_str_mv AT toledosergiopa hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
AT lourencojrdelmarm hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
AT santosmarceloaugusto hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
AT tavaresmarcosr hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
AT toledorodrigoa hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
AT correiadeurjoyaemiliedemenezes hypercalcitoninemiaisnotpathognomonicofmedullarythyroidcarcinoma
_version_ 1756432048837361664